BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Docket Clock//docket-clock.pages.dev//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:FDA CMC (chemistry\, manufacturing & controls) deadlines (Doc
 ket Clock)
X-PUBLISHED-TTL:PT12H
REFRESH-INTERVAL;VALUE=DURATION:PT12H
BEGIN:VEVENT
UID:2026-17222-close@docket-clock.pages.dev
DTSTAMP:20261017T145145Z
DTSTART;VALUE=DATE:20261023
DTEND;VALUE=DATE:20261024
SUMMARY:FDA comments close: Product-Specific Guidances\; Draft and Revised
  Draft Guidances for Industry\; Availability
DESCRIPTION:Notice. Federal Register 2026-17222. Docket FDA-2007-D-0369. D
 etails: https://docket-clock.pages.dev/doc/2026-17222/ Official: https://
 www.federalregister.gov/documents/2026/08/24/2026-17222/product-specific-
 guidances-draft-and-revised-draft-guidances-for-industry-availability
URL:https://www.federalregister.gov/documents/2026/08/24/2026-17222/produc
 t-specific-guidances-draft-and-revised-draft-guidances-for-industry-avail
 ability
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2026-16960-close@docket-clock.pages.dev
DTSTAMP:20261017T145145Z
DTSTART;VALUE=DATE:20261118
DTEND;VALUE=DATE:20261119
SUMMARY:FDA comments close: Potency Assessment of Active Immunotherapy Pro
 ducts\; Draft Guidance for Industry\; Availability
DESCRIPTION:Notice. Federal Register 2026-16960. Docket FDA-2026-D-8561. D
 etails: https://docket-clock.pages.dev/doc/2026-16960/ Official: https://
 www.federalregister.gov/documents/2026/08/20/2026-16960/potency-assessmen
 t-of-active-immunotherapy-products-draft-guidance-for-industry-availabili
 ty
URL:https://www.federalregister.gov/documents/2026/08/20/2026-16960/potenc
 y-assessment-of-active-immunotherapy-products-draft-guidance-for-industry
 -availability
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR